HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.310

-0.070-0.67%

Volume:4.54M

Turnover:46.60M

Market Cap:4.20B

PE:-11.63

High:10.440

Open:10.440

Low:10.120

Close:10.380

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.52

T/O Rate:1.46%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.887

ROE:-62.88%

ROA:-32.06%

PB:8.64

PE(LYR):-11.63

PS:- -

Loading ...

Overview Company News Filings

TransThera Sciences (Nanjing) Buys Back 217,000 H-Shares for HKD 2.24 Million, Lifting Treasury Stock to 718,000 Shares

Bulletin Express

TRANSTHERA-B (02617) Invests HK$1.133 Million in Share Buyback on July 23

Transthera Sciences Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation

TransThera-B completes on-market buyback of 105,000 H shares, treasury stock rises to 396,000

Bulletin Express

TransThera Sciences buys back 111,000 H-shares, lifts treasury stock to 291,000 units

Bulletin Express

TRANSTHERA-B Allocates HK$1.14 Million for Share Buyback on July 21

Transthera Sciences Files HKEX Next-day Disclosure Return After Share Repurchase for Treasury Shares

TRANSTHERA-B Announces Share Buyback Totaling HK$1.12 Million on July 20

Movement Alert｜Yaojie Ankang-B Declines 8.13% in Regular Trading, Trading at 9.83 HKD

TransThera's TT-00973 Cleared for China Phase 2 Lung Cancer Trial

MT Newswires Live

Transthera Sciences (nanjing) Says NMPA Approves Phase II Trial of Tt-973 with Firmonertinib Mesylate

TRANSTHERA-B Receives Regulatory Nod for Phase II Trial of TT-00973 in Combination with Furmonertinib for NSCLC

TransThera gains NMPA clearance to launch Phase II study of TT-00973 plus firmonertinib in EGFR-mutant NSCLC

Bulletin Express

Transthera Sciences (nanjing) - Nmpa Approves Phase Ii Trial of Tt-973 with Firmonertinib Mesylate on July 10, 2026

THOMSON REUTERS

Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib

Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan

Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval

From $270 Billion to $4.1 Billion: This Small Biotech, With Just Over 100 Employees, Is Undertaking What Giants Dare Not Attempt

Movement Alert｜TransThera Sciences Rises 6.93% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment and New Pipeline Gains Approval

TransThera Sciences Completes Patient Enrollment for Cholangiocarcinoma Drug Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02617/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.31,"timestamp":1787299687057,"preClose":10.38,"halted":0,"volume":4543800,"delay":0,"changeRate":-0.006743737957610817,"floatShares":312000000,"shares":407000000,"eps":-0.8868345239122081,"marketStatus":"Market Closed","change":-0.07,"latestTime":"08-21 16:08:07","open":10.44,"high":10.44,"low":10.12,"amount":46601191,"amplitude":0.030829,"askPrice":10.31,"askSize":5000,"bidPrice":10.3,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.8863140920731754,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.38,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5223118835745755,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-32.06%","roe":"-62.88%","lyrEps":-0.886835,"volumeRatio":0.5223118835745755,"shares":407000000,"dividePrice":0,"high":10.44,"amplitude":0.030829,"preClose":10.38,"low":10.12,"week52Low":9.01,"pbRate":"8.64","week52High":679.5,"institutionHeld":0,"latestPrice":10.31,"committee":0.354839,"eps":-0.8868345239122081,"divideRate":0,"volume":4543800,"delay":0,"ttmEps":-0.8863140920731754,"open":10.44,"prevYearClose":114.9,"prevWeekClose":10.33,"prevMonthClose":9.95,"prevQuarterClose":11.55,"fiveDayClose":10.33,"twentyDayClose":10.19,"sixtyDayClose":38.7,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-21","current":-11.632445,"percent":0.95122,"low":-380.446233,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"high":-10.87103,"avg":-114.757849,"sd":96.187407,"marketCap":4205641106},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106}],"updateTime":1787446946256},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1191390297","title":"TransThera Sciences (Nanjing) Buys Back 217,000 H-Shares for HKD 2.24 Million, Lifting Treasury Stock to 718,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1191390297","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191390297?lang=en_us&edition=fundamental","pubTime":"2026-07-24 18:42","pubTimestamp":1784889743,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) disclosed that it repurchased 217,000 H-shares on 24 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were acquired...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183283569","title":"TRANSTHERA-B (02617) Invests HK$1.133 Million in Share Buyback on July 23","url":"https://stock-news.laohu8.com/highlight/detail?id=1183283569","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183283569?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:12","pubTimestamp":1784808726,"startTime":"0","endTime":"0","summary":"The company TRANSTHERA-B (02617) has announced a share repurchase transaction.On July 23, 2026, the company utilized HK$1.133 million to repurchase 105,000 of its own shares.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653747784","title":"Transthera Sciences Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653747784","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653747784?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:08","pubTimestamp":1784808480,"startTime":"0","endTime":"0","summary":"Transthera Sciences files HKEX next-day return disclosing share repurchase for cancellationTransthera Sciences repurchased 105,000 H shares on July 23, holding them as treasury shares.Buyback priced a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL3x6qYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110558146","title":"TransThera-B completes on-market buyback of 105,000 H shares, treasury stock rises to 396,000","url":"https://stock-news.laohu8.com/highlight/detail?id=1110558146","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110558146?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:03","pubTimestamp":1784721808,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118651014","title":"TransThera Sciences buys back 111,000 H-shares, lifts treasury stock to 291,000 units","url":"https://stock-news.laohu8.com/highlight/detail?id=1118651014","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118651014?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:43","pubTimestamp":1784637785,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. reported that on 21 July 2026 it repurchased 111,000 H-shares on the Hong Kong Stock Exchange for treasury purposes. The buy-back was executed within a price band...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151207063","title":"TRANSTHERA-B Allocates HK$1.14 Million for Share Buyback on July 21","url":"https://stock-news.laohu8.com/highlight/detail?id=1151207063","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151207063?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:20","pubTimestamp":1784636418,"startTime":"0","endTime":"0","summary":"The biopharmaceutical company TRANSTHERA-B (02617) has announced the execution of a share repurchase transaction.On July 21, 2026, the firm utilized approximately HK$1.14 million to buy back 111,000 of its own shares.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277375","title":"Transthera Sciences Files HKEX Next-day Disclosure Return After Share Repurchase for Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277375","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277375?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:17","pubTimestamp":1784636226,"startTime":"0","endTime":"0","summary":"Transthera Sciences files HKEX next-day disclosure return after share repurchase for treasury sharesTransthera Sciences (Nanjing) repurchased 111,000 H shares on July 21, 2026 for treasury at HKD 9.92","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDLbqgZBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194027454","title":"TRANSTHERA-B Announces Share Buyback Totaling HK$1.12 Million on July 20","url":"https://stock-news.laohu8.com/highlight/detail?id=1194027454","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194027454?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:30","pubTimestamp":1784543419,"startTime":"0","endTime":"0","summary":"On July 20, 2026, TRANSTHERA-B (02617) executed a share repurchase, utilizing approximately HK$1.12 million to acquire 112,000 of its own shares.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136767784","title":"Movement Alert｜Yaojie Ankang-B Declines 8.13% in Regular Trading, Trading at 9.83 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1136767784","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136767784?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:37","pubTimestamp":1784255879,"startTime":"0","endTime":"0","summary":"On July 17, Yaojie Ankang-B (02617.HK) fell 8.13% in regular trading, trading at 9.83 HKD/share, with turnover of approximately 60.28 million HKD.Within the Biotechnology sector where Yaojie Ankang-B...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651716009","title":"TransThera's TT-00973 Cleared for China Phase 2 Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651716009","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651716009?lang=en_us&edition=fundamental","pubTime":"2026-07-13 12:01","pubTimestamp":1783915285,"startTime":"0","endTime":"0","summary":"TransThera Sciences  said China's National Medical Products Administration approved a Phase 2 clinical trial of its TT-00973 tablets in combination with firmonertinib mesylate, according to a July 10 Hong Kong bourse filing.The combination will be evaluated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR-sensitive mutations.The multi-center, open-label study will assess the safety and efficacy of the combination therapy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ1G4Q59.USD","SG9999002224.SGD","LU1732800096.USD","LU2211814178.USD","LU2279689827.SGD","LU0070217475.USD","BK4588","LU1718418525.SGD","LU2764263203.CNY","IE0004091025.USD","LU0266013472.USD","LU2552382132.HKD","LU2720916845.USD","IE0004086264.USD","IE00B2PGVK34.USD","LU2089279066.USD","BK4504","LU0323240290.USD","LU0238689110.USD","BK4086","LU2347655073.USD","LU2229751404.USD","LU1732799900.SGD","BK1161","LU2211817866.USD","LU2552382215.SGD","BK4533","LU2764262908.HKD","LU0912757837.SGD","LU2394011477.USD","BK4585","LU0154245756.USD","LU0323239441.USD","LU0795875169.SGD","IE00BKVL7J92.USD","LU2133065610.SGD","IE00BGHQF417.EUR","LU2463526074.USD","LU0210533765.USD","TT","LU2552382058.USD","02617","LU0154245673.USD","LU2347655156.SGD","LU2764263039.SGD","SG9999002232.USD","LU0795875086.SGD","LU0726765562.USD","IE00B3CCJ633.GBP"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2650378139","title":"Transthera Sciences (nanjing) Says NMPA Approves Phase II Trial of Tt-973 with Firmonertinib Mesylate","url":"https://stock-news.laohu8.com/highlight/detail?id=2650378139","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650378139?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:31","pubTimestamp":1783697473,"startTime":"0","endTime":"0","summary":"July 10 (Reuters) - TransThera Sciences (Nanjing) Inc <2617.HK>::*NMPA APPROVES PHASE II TRIAL OF TT-973 WITH FIRMONERTINIB MESYLATE ON JULY 10, 2026*Further company coverage: 2617.HK* ((Reuters.Brief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nRSD5nKzfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167220060","title":"TRANSTHERA-B Receives Regulatory Nod for Phase II Trial of TT-00973 in Combination with Furmonertinib for NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1167220060","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167220060?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:24","pubTimestamp":1783693470,"startTime":"0","endTime":"0","summary":"Clinical trial approval has been granted for a Phase II study of TRANSTHERA-B's (ASX: 02617) investigational drug TT-00973 in combination with furmonertinib for a specific type of lung cancer.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","IBBQ","IE0004086264.USD","LU2229751404.USD","LU2552382215.SGD","LU2211817866.USD","LU2279689827.SGD","LU2347655073.USD","LU2552382058.USD","02617","LU0726765562.USD","IE00BGHQF417.EUR","BK4585","LU0323239441.USD","LU0070217475.USD","BK4086","LU2089279066.USD","LU2764263039.SGD","BK4504","LU0795875169.SGD","LU2552382132.HKD","LU1732800096.USD","BK4588","TT","BK1161","BK4533","LU1732799900.SGD","LU2463526074.USD","LU0266013472.USD","LU0210533765.USD","SG9999002224.SGD","LU1718418525.SGD","LU2347655156.SGD","IE00BKVL7J92.USD","LU0795875086.SGD","LU2764262908.HKD","IE00B3CCJ633.GBP","BMED","LU0323240290.USD","IE00BZ1G4Q59.USD","LU0912757837.SGD","LU2133065610.SGD","LU0154245673.USD","LU2394011477.USD","IE00B2PGVK34.USD","LU2720916845.USD","LU0238689110.USD","IE0004091025.USD","LU0154245756.USD","LU2764263203.CNY","LU2211814178.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184982898","title":"TransThera gains NMPA clearance to launch Phase II study of TT-00973 plus firmonertinib in EGFR-mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1184982898","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184982898?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:23","pubTimestamp":1783693419,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera, HKEX: 02617) has secured National Medical Products Administration approval, dated 10 July 2026, to initiate a multi-centre, open-label Phase II trial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135665","title":"Transthera Sciences (nanjing) - Nmpa Approves Phase Ii Trial of Tt-973 with Firmonertinib Mesylate on July 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650135665?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:18","pubTimestamp":1783693085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C0FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185228112","title":"Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1185228112","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185228112?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:12","pubTimestamp":1783653127,"startTime":"0","endTime":"0","summary":"On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.On the news front, the company announced on July 1 that its core product...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135423515","title":"Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1135423515","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135423515?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:30","pubTimestamp":1783305047,"startTime":"0","endTime":"0","summary":"On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103684444","title":"Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1103684444","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103684444?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:51","pubTimestamp":1783043474,"startTime":"0","endTime":"0","summary":"On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127655442","title":"From $270 Billion to $4.1 Billion: This Small Biotech, With Just Over 100 Employees, Is Undertaking What Giants Dare Not Attempt","url":"https://stock-news.laohu8.com/highlight/detail?id=1127655442","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127655442?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:27","pubTimestamp":1782984462,"startTime":"0","endTime":"0","summary":"The market valuation of TRANSTHERA-B (02617) has plummeted from a historical peak of HK$270 billion to approximately HK$4.1 billion. On June 23rd, the company entered the second phase of a post-IPO...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156797201","title":"Movement Alert｜TransThera Sciences Rises 6.93% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment and New Pipeline Gains Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1156797201","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156797201?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:25","pubTimestamp":1782959132,"startTime":"0","endTime":"0","summary":"On July 2, TransThera Sciences-B (02617.HK) rose 6.93% in regular trading, reaching HK$12.29 per share, with turnover of HK$317 million.On the news front, the company released two R&D progress...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648543329","title":"TransThera Sciences Completes Patient Enrollment for Cholangiocarcinoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648543329","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648543329?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:32","pubTimestamp":1782909170,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) (HKG:2617) completed enrollment for a phase III trial of Tinengotinib.The drug is being tested for the treatment of patients with advanced cholangiocarcinoma, according to a Wednesday Hong Kong bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":140,"code":"91000000","status":"200"}]}}